CRISPR gene editing has made rapid progress heading from bench to bedside. Perhaps the fastest has been its progress toward clinical use to combat sickle cell disease. We’ll start with a new paper on one major effort here. CRISPR gene editing. This process often involves cutting DNA, which then can be used as an opening to […]
Weekly reads: CRISPR sickle cell, Parkinson’s, pig-human chimera concerns Read More »
Several groups including Viviane Tabar who is a founding scientist at BlueRock Therapeutics are moving forward on potential cell therapies for Parkinson’s Disease. BlueRock just released some new data that’s worth a look. Check out the new BlueRock poster. In today’s post, I briefly discuss the new data. I also go into the larger context
Small positive step for BlueRock Therapeutics Stem Cell Therapy for Parkinson’s Read More »
Early during my postdoc I was primarily interested in the role of Myc genes both in cancer and in stem cells, work that later included embryonic stem cells. These cells are often called ES cells. At first I first started studying N-Myc in neural stem cells using a conditional knockout approach. However, soon after I was
Weekly reads: embryonic stem cells, Parkinson’s, Alzheimer’s Read More »
It’s been almost seventeen years that I’ve been a professor here at UC Davis Medical School. It feels like home. I enjoy teaching our first-year medical students each year. Some end up doing research in my lab. Our school recently got a nice write-up over at STAT News by Usha Lee McFarling on the diversity
Weekly reads: UC Davis Medical School diversity, CRISPR, Parkinson’s Read More »
This edition of The Niche weekly reads has a bit more good news than usual including on stem cell transplants. It’s nice to see positive developments like some recipients of hematopoietic stem cell transplants being able to stay at home afterwards. Also, a reminder. You have until July 31 to enter our stem cell video
I’m playing catch-up on some reading given how busy I’ve been and this includes a groundbreaking NEJM pub on CRISPR for Sickle Cell and Thalassemia. CRISPR for Sickle Cell From December, here’s the key paper in the NEJM: CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. There’s a lot to like about this clinical
Recommended reads: CRISPR for Sickle Cell, Parkinson’s, & more Read More »
I find following both stem cell news and the stream of interesting publications to be kind of fun and thought-provoking. This past week or two has been very busy. Here is a news summary and list of notable pubs. Stem Cell News on Parkinson’s Disease There were a number of interesting developments on the Parkinson’s
Stem cell news & pubs: Parkinson’s, Freezing, COVID, & More Read More »
Where do things stand today in 2020 with IPS cell research? It’s been 14 years since they were first reported, but they continue to make news. Back in 2006 I was wrapping up my postdoc with Bob Eisenman at The Hutch in Seattle, largely studying Myc, when Shinya Yamanaka published his first induced pluripotent stem
IPS cell field update: easy culture, Parkinson’s, scarring, immune cells, & mutations Read More »
In Parkinson’s Disease patients develop neurological dysfunction as they lose a special kind of brain cell called dopaminergic (or dopamine) neurons. While a number of different approaches to this disease have been studied for decades, nothing has proven particularly successful in slowing its progression. As a result there has been a big need for novel thinking
Hope on Parkinson’s front: Japan IPSC trial 1st patient Read More »
By Jeanne Loring There are ten million people in the world who have Parkinson’s disease. 125,000 of these are living in California. People with the disease often have to step away from their jobs because the main symptoms – tremor or freezing up of muscles – make it difficult to get through a whole day
On the threshold of cell therapy for Parkinson’s disease Read More »